The purpose of this study is to evaluate the effectiveness of 2.5mg empagliflozin (Jardiance) in improving glucose control in people living with type 1 diabetes using an insulin pump. We’re recruiting adults with type 1 diabetes using an advanced automated insulin pump (ex: Medtronic 780G, Tandem t:slim, etc.) with a sub-optimal glycemic outcomes (TIR below 70%). The study will last between 6-7 months and includes 3 visits of about 60-90mins.
Sponsor
Diabetes Canada
Principle Investigator
Melissa-Rosina Pasqua
Researchers
Adelyn Moore
Co-investigators
Rémi Rabasa-Lhoret
Bruce Perkins
Recruiting time left
Days
:
Hours
:
Minutes
:
Seconds
Contribute
Participating in research not only gives you access to innovative treatments, but also allows you to contribute to the discovery of new therapies.